• News
  • Stock Screener
  • Small Caps
  • Guru portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Brazil·Healthcare·PFRM3.SA
Share

Profarma Distribuidora de Produtos Farmaceuticos S.A. Stocks

R$ 6.7Last Updated 15.05.2026

Issuer Rating

5/7
Performance

Strong

Risk

Moderate

Recommendation

Hold

Market Cap

R$ 162.52M

R$ 6.7
Key Takeaways

Risk factor

Poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Profarma Distribuidora de Produtos Farmacêuticos S.A., together with its subsidiaries, engages in the distribution and retail sale of pharmaceutical and hospital products in Brazil. The company operates through Distribution, and Retail segments. It provides branded medicines, generic drugs, and over-the-counter (OTC) medicines; personal hygiene, beauty, and cosmetic products, such as shampoos, conditioners, treatment creams and hair dyes, diapers and children's products, soaps , deodorants, oral care products, sunscreens, male products, cosmetics, makeup and skin products, and others; and hospital products, including injectable and infusion drugs for oncology, endocrinology, rheumatology, infectology, hematology, and other specialties. The company also offers vaccines for influenza, HPV, meningitis, hepatitis, chickenpox, dengue, and other diseases; special medicines intended for the treatment of rare and complex diseases; exclusive hygiene and beauty products, vitamins, and workshops products under the Nº21, GOnutri, and Bem Básico brands; and convenience products, including food products, pressure gauges, scales, and related products. In addition, it provides complementary services, such as promotional and logistical support, implementation of promotional campaigns, product recall, development of customized projects to offer laboratories solutions, and management of clinical procedures. As of December 31, 2019, the company operated eleven distribution centers located in the states of Alagoas, Bahia, Espírito Santo, Goiás, Minas Gerais, Paraíba, Paraná, Pernambuco, Rio Grande do Sul, Rio de Janeiro, and São Paulo, as well as approximately 196 stores in the states of Rio de Janeiro, Goiás, Tocantins, Mato Grosso, and Distrito Federal under the Drogarias Tamoio, Drogasmil, Farmalife, and Rede Rosário brands. The company was founded in 1961 and is headquartered in Rio de Janeiro, Brazil.

Company Valuation

Greatly undervalued
7/7

Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers. In particular, the stock is underpriced on P/E, 'cheap' on EV/EBIT

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

18.05.2026 09:50

"The clock is ticking": oil hits Ma record after Trump ultimatum and nuclear power plant attack

17.05.2026 21:00

SpaceX's listing date and rival Nvidia's record: what's important about the IPO by Ma. 17

17.05.2026 18:01

Downgrade game-1789: how a relocant from Geneva made money before the French Revolution

17.05.2026 15:01

Frustration and reward: how to get rid of the tendency to over-trade

16.05.2026 17:18

Main in small-caps: BuzzFeed deal, bets on AI boom, forecast from BNP Paribas AM

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026